Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.

BMC medicine - 2 Feb 2021

Zhang Zhen, Wu Hao-Xiang, Lin Wu-Hao, Wang Zi-Xian, Yang Lu-Ping, Zeng Zhao-Lei, Luo Hui-Yan

Abstract excerpt

BACKGROUND: A critical and challenging process in immunotherapy is to identify cancer patients who could benefit from immune checkpoint inhibitors (ICIs). Exploration of predictive biomarkers could help to maximize the clinical benefits. Eph receptors have been shown to play essential roles in tumor immunity. However, the association between EPH gene mutation and ICI response is lacking. METHODS: Clinical data...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cohort Studies
Share to DNA Copy Number Variations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Mutation

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 33526018
DOI: 10.1186/s12916-020-01899-x
PMCID: PMC7852135

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.PMID 33526018Read ↗

Systematic Pan-Cancer Analysis Reveals the Prognostic Value and Immunological Role of EPHX2Semantic proximity Read ↗

EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma.Semantic proximity Read ↗

EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma.Semantic proximity Read ↗

Comprehensive analysis of EphA2 in pan-cancer: A prognostic biomarker associated with cancer immunity.Semantic proximity Read ↗

EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinomaSemantic proximity Read ↗

Association of EPHA3 mutations with tumor mutational burden and efficacy of immune checkpoint inhibitors in cancer patientsSemantic proximity Read ↗

Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.Semantic proximity Read ↗

EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma.Semantic proximity Read ↗

The role of EPHA3 mutation in the prognosis of non-small cell lung cancer patients receiving immunotherapySemantic proximity Read ↗

Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC.Semantic proximity Read ↗

A comprehensive prognostic and immunological analysis of ephrin family genes in hepatocellular carcinomaSemantic proximity Read ↗

Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.